We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune... CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure. Show more
CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) PR Newswire LA JOLLA, Calif., June 27, 2024 Primary objective of the trial met with...
CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) PR Newswire LA JOLLA, Calif., June 26, 2024 Conference call and webcast...
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates PR Newswire LA JOLLA, Calif., May 13, 2024 Last patient enrolled in CARPO, Phase 2b trial of...
CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024 PR Newswire LA JOLLA, Calif., May 7, 2024 Collaborators from Cedars-Sinai to present human proteomics data supporting...
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis PR Newswire LA JOLLA, Calif., April 24, 2024 Full target enrollment of 216 patients...
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates PR Newswire LA JOLLA, Calif., March 28, 2024 Enrollment in CARPO, Phase 2b trial of Auxora™ in acute...
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference PR Newswire LA JOLLA, Calif., March 13, 2024 Therapeutic...
CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference PR Newswire LA JOLLA, Calif., Feb. 28...
CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury PR Newswire LA JOLLA, Calif., Feb. 13, 2024 Phase 2 trial...
CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire LA JOLLA, Calif., Feb. 7, 2024 LA JOLLA, Calif., Feb. 7, 2024 /PRNewswire/ -- CalciMedica...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 5.17 | 5.4 | 3.0615 | 197739 | 3.42668713 | CS |
| 4 | 0 | 0 | 5.74 | 5.9 | 3.0615 | 58338 | 3.61731317 | CS |
| 12 | 0 | 0 | 4.2594 | 6.265 | 3.0615 | 31956 | 4.2927818 | CS |
| 26 | 0 | 0 | 2.9 | 8.38 | 2.68 | 26559 | 4.50706629 | CS |
| 52 | 0 | 0 | 4.09 | 8.38 | 1.75 | 20734 | 3.94611632 | CS |
| 156 | 0 | 0 | 5.27 | 8.59 | 1.75 | 22499 | 4.10298023 | CS |
| 260 | 0 | 0 | 5.27 | 8.59 | 1.75 | 22499 | 4.10298023 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
